OTCMKTS:HLUYY H. Lundbeck A/S (HLUYY) Stock Price, News & Analysis → Protect Your Bank Account from China (From Behind the Markets) (Ad) Free HLUYY Stock Alerts $22.00 -0.01 (-0.02%) (As of 08/9/2022) Add Compare Share Share Today's Range$22.00▼$24.0050-Day Range$22.00▼$22.0052-Week Range$10.00▼$31.55Volume7,500 shsAverage Volume1,758 shsMarket Capitalization$21.91 billionP/E Ratio25.00Dividend Yield0.91%Price TargetN/A Stock AnalysisStock Analysis Get H. Lundbeck A/S alerts: Email Address Ad Behind the MarketsThis Weight Loss Company Can't Make Enough ProductA tiny pharmaceutical company is getting overwhelmed by a massive demand for its new weight loss marvel. They recently reported over 25,000 Americans are starting their drug each week - a 4X increase since December!Get the name of the company and their stock ticker here >>> About H. Lundbeck A/S Stock (OTCMKTS:HLUYY)H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.Read More HLUYY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HLUYY Stock News HeadlinesMay 17, 2024 | morningstar.comH. Lundbeck AS Class A HLUN AMay 2, 2024 | msn.comBluey’s Big Play coming to Buddy Holly Hall in AugustApril 26, 2024 | seekingalpha.comGIFLF Grifols, S.A.April 22, 2024 | msn.comNew Hampshire's 'Kid Conservationist' joins 'Jennifer Hudson Show' for Earth DayApril 16, 2024 | finance.yahoo.comH. Lundbeck A/S (LDBB.F)April 15, 2024 | msn.com‘Vanished’: 25 years since Nathan Edberg’s vehicle was found abandoned in Vadnais Heights, search for answers continuesMarch 25, 2024 | fool.comH. Lundbeck A/s (OTC: HLUYY)February 23, 2024 | investing.comH Lundbeck A/S ADR (HLUYY)February 11, 2024 | msn.comWWE: Becky Lynch gives fans a preview of what to expect from her bookJanuary 19, 2024 | msn.comA Chilling New Twist in the Lindbergh Baby Mystery Could Actually Flip the VerdictAugust 23, 2023 | wsj.comH. Lundbeck A/S Cl AAugust 11, 2023 | msn.com‘Finding W.H. Hudson’ Review: The Enigmatic BirdmanAugust 8, 2023 | nytimes.comTo Have and to Hold, Even if You Turn Into a Literal SharkJuly 18, 2023 | uk.investing.comH Lundbeck B (0ND5)May 12, 2023 | msn.comH. Lundbeck A/S reports Q1 resultsFebruary 8, 2023 | msn.comH. Lundbeck A/S reports FY resultsNovember 24, 2022 | finance.yahoo.comH. Lundbeck A/S (HLUN-B.CO)October 20, 2022 | investing.comH Lundbeck B (HLUNb)September 14, 2022 | msn.comMonica Lewinsky's Response to Death of Clinton Prosecutor Ken Starr PraisedSeptember 13, 2022 | msn.comWatch Lucid's Boss Spend an Hour Explaining How the Air's Motor WorksSeptember 9, 2022 | msn.comEveryone's Saying The Same Thing About Odell Beckham Jr. TonightSeptember 6, 2022 | msn.comSlain Memphis jogger Eliza Fletcher was a 2010 graduate of Baylor UniversitySeptember 3, 2022 | msn.comFormer Lutz Children’s Museum director busted on child pornography chargesSeptember 2, 2022 | yahoo.comFormer children’s museum director pleads guilty to child pornography chargesSeptember 2, 2022 | msn.comFormer executive director for Manchester children's museum pleads guilty to distributing child pornographySee More Headlines Receive HLUYY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for H. Lundbeck A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2015Today6/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private Households Sub-IndustryN/A Current SymbolOTCMKTS:HLUYY CUSIPN/A CIKN/A Webwww.lundbeck.com Phone(453) 630-1311Fax45-3630-1940Employees5,348Year Founded1915Profitability EPS (Most Recent Fiscal Year)$0.88 Trailing P/E Ratio25.00 Forward P/E Ratio10.48 P/E GrowthN/ANet Income$209.69 million Net Margins6.74% Pretax Margin7.83% Return on Equity13.74% Return on Assets7.16% Debt Debt-to-Equity Ratio0.32 Current Ratio1.15 Quick Ratio0.71 Sales & Book Value Annual Sales$2.59 billion Price / Sales8.45 Cash Flow$3.36 per share Price / Cash Flow6.54 Book Value$14.60 per share Price / Book1.51Miscellaneous Outstanding Shares995,741,000Free FloatN/AMarket Cap$21.91 billion OptionableNot Optionable Beta0.68 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Deborah Dunsire M.D. (Age 60)Pres & CEO Comp: $7.16MMr. Jacob Tolstrup (Age 50)Exec. VP of Commercial Operations & Chief Commercial Officer Comp: $888.17kMr. Lars Bang (Age 60)Exec. VP of Product Devel. & Supply Comp: $915.5kDr. Per Johan Luthman (Age 63)Exec. VP of R&D Comp: $901.84kMr. Bjorn R. MogensenSr. VP Group Fin.Dr. Tarek Samad Ph.D.Sr. VP & Head of ResearchMr. Palle Holm OlesenChief Specialist & VP of Investor RelationsMs. Elise Hauge (Age 55)Exec. VP of People & Communication Mr. Ole Chrintz (Age 64)Sr. VP of International Markets Mr. Keld Flintholm Jorgensen (Age 51)Exec. VP of Corp. Strategy & Bus. Devel. More ExecutivesKey CompetitorsBYDOTCMKTS:BYDDYUniCreditOTCMKTS:UNCFFBYDOTCMKTS:BYDDFIberdrolaOTCMKTS:IBDRYRecruitOTCMKTS:RCRRFView All Competitors Should I Buy H. Lundbeck A/S Stock? HLUYY Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in H. Lundbeck A/S: Recent positive developments in the company's pipeline, indicating potential for future growth and innovation. Strong financial performance with consistent revenue growth and profitability, providing stability for investors. Current stock price showing an upward trend, suggesting market confidence and potential for capital appreciation. Strategic partnerships and collaborations that could lead to new market opportunities and increased market share. Focus on research and development, ensuring a competitive edge in the pharmaceutical industry and potential for breakthrough products. Cons Investors should be bearish about investing in H. Lundbeck A/S for these reasons: Market volatility and regulatory challenges in the pharmaceutical sector could impact the company's performance and stock value. Dependency on a few key products for a significant portion of revenue, posing a risk if any of these products face setbacks. Competition from generic drug manufacturers affecting pricing and market share of H. Lundbeck A/S products. Currency exchange rate fluctuations impacting international sales and profitability. Uncertainty in global economic conditions affecting overall demand for pharmaceutical products and healthcare services. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, June 4, 2024. Please send any questions or comments about these H. Lundbeck A/S pros and cons to contact@marketbeat.com. HLUYY Stock Analysis - Frequently Asked Questions Should I buy or sell H. Lundbeck A/S stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for H. Lundbeck A/S in the last twelve months. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" HLUYY shares. View HLUYY analyst ratings or view top-rated stocks. How have HLUYY shares performed in 2024? H. Lundbeck A/S's stock was trading at $22.00 at the beginning of 2024. Since then, HLUYY stock has increased by 0.0% and is now trading at $22.00. View the best growth stocks for 2024 here. How were H. Lundbeck A/S's earnings last quarter? H. Lundbeck A/S (OTCMKTS:HLUYY) announced its quarterly earnings data on Wednesday, November, 4th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.01 by $0.16. The company earned $547.05 million during the quarter, compared to the consensus estimate of $514.82 million. H. Lundbeck A/S had a trailing twelve-month return on equity of 13.74% and a net margin of 6.74%. Is H. Lundbeck A/S a good dividend stock? H. Lundbeck A/S (OTCMKTS:HLUYY) pays an annual dividend of $0.20 per share and currently has a dividend yield of 0.91%. The dividend payout ratio is 22.73%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, HLUYY will have a dividend payout ratio of 7.02% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for HLUYY. How do I buy shares of H. Lundbeck A/S? Shares of HLUYY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does H. Lundbeck A/S have any subsidiaries? The following companies are subsidiares of H. Lundbeck A/S: Alder BioPharmaceuticals, and Prexton Therapeutics.Read More This page (OTCMKTS:HLUYY) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredInflation Is Robbing You Blind! Here’s How to Fight Back!Quietly, inflation has reduced your purchasing power by 29.4% since 2014. So something that cost $100 in 20...American Alternative | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding H. Lundbeck A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share H. Lundbeck A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.